Phio Pharmaceuticals Corp
phiopharma.comWhat Do They Do?
Develops RNA-based drug candidates designed to help immune cells kill tumor cells, for patients with cancer.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$4.1MView ↗
- ▲ +91% (Loss)
- vs −$2.2M in Q2 FY2025
-
Sep 14, 2026
Submits PH-762 materials to FDA and plans Phase 2b study
The submission supports next-phase clinical development in cutaneous cell carcinoma.
Sources
8-K, filed Sep 14, 2026
On September 14, 2026, the Company issued a press release announcing a key development milestone for PH-762, including the submission of…View ↗
Clinical study focus
The older report described a study in France focused on advanced melanoma; the latest report describes a U.S. study covering cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 5, 2026PH-762 is currently being evaluated in a Phase 1b dose escalation clinical trial in France that is expected to enroll up to 21 subjects…View ↗
PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of…View ↗
Pipeline priorities
The older report said one candidate's IND-enabling studies were complete and reports were being finalized; the latest says that candidate's submission is deferred while the company advances its lead clinical candidate.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 5, 2026Preclinical studies conducted have demonstrated that PH-894 resulted in a strong, concentration dependent and durable silencing of BRD4 in…View ↗
Preclinical studies conducted have demonstrated that PH-894 resulted in a strong, concentration dependent and durable silencing of BRD4 in…View ↗
Loading...
